Expertise in
6
conditions

Dr. Gihan I. Tennekoon

Neurology
Office
3401 Civic Center Blvd, 
Philadelphia, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
6
conditions
Office
3401 Civic Center Blvd, 
Philadelphia, PA 

Overview

Gihan Tennekoon is a Neurologist practicing medicine in Philadelphia, Pennsylvania.

Dr. Tennekoon is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Spinal Muscular Atrophy (SMA), and Primary Lateral Sclerosis.

He is actively involved in clinical research, co-authoring 34 peer reviewed articles and participating in 8 clinical trials.

Specialties

Neurology

Licenses

Psychiatry & Neurology in PA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Office
3401 Civic Center Blvd, Philadelphia, PA 19104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Enrollment Status: Completed
Publish Date: January 26, 2026
Intervention Type: Biological
Study Phase: Phase 3
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Enrollment Status: Terminated
Publish Date: January 26, 2026
Intervention Type: Biological
Study Phase: Phase 1
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: February 02, 2023
Intervention Type: Drug
Study Drug: Givinostat
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

34 Total Publications

Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG).
Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG).
Journal: Journal of neuromuscular diseases
Published: March 13, 2023
Similar Doctors
Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required
Before you request

Penn Neuroscience Center - Neurology

3400 Civic Center Boulevard, South Pavilion, 2nd Floor, 
Philadelphia, PA 
 (0.1 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Lynch is a Neurologist practicing medicine in Philadelphia, Pennsylvania. Dr. Lynch is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Friedreich Ataxia, Spinocerebellar Ataxia, Drug Induced Dyskinesia, Hereditary Ataxia, and Spinal Fusion. Dr. Lynch is board certified in Neurology, 1993. Dr. Lynch is currently accepting new patients.

Expertise in
48
conditions
Expertise in
48
conditions
Referral may be required
Before you request

Penn Nerve Center University City

3737 Market Street, 7th Floor, 
Philadelphia, PA 
 (0.6 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lauren Elman is a Neurologist practicing medicine in Philadelphia, Pennsylvania. Dr. Elman is highly rated in 48 conditions, according to our data. Her clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Myotonic Dystrophy, and Myotonic Dystrophy Type 2. Dr. Elman is board certified in Neurology, 2003. Dr. Elman is currently accepting new patients.

Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required
Before you request

Vickie & Jack Farber Institute For Neuroscience - Honickman Center

1101 Chestnut Street, Floor 10, 
Philadelphia, PA 
 (1.9 miles away)
215-955-1222
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Sperling is a Neurologist practicing medicine in Philadelphia, Pennsylvania. Dr. Sperling is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Seizures, Epilepsy, Generalized Tonic-Clonic Seizure, Absence Seizure, and Deep Brain Stimulation. Dr. Sperling is board certified in Neurology. Dr. Sperling is currently accepting new patients.

Frequently Asked Questions about Dr. Gihan I. Tennekoon

How do I make an appointment with Dr. Gihan I. Tennekoon?

You can book an appointment with Dr. Gihan I. Tennekoon by calling their office at 215-590-1000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Gihan I. Tennekoon a top-rated expert for Duchenne Muscular Dystrophy?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Gihan I. Tennekoon is classified as an Distinguished expert for Duchenne Muscular Dystrophy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Gihan I. Tennekoon specialize in?

While Dr. Gihan I. Tennekoon is a Neurology, they have specific expertise in Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Spinal Muscular Atrophy (SMA). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Gihan I. Tennekoon participate in research or clinical trials?

Yes. Dr. Gihan I. Tennekoon has published 34 articles and abstracts on conditions like Duchenne Muscular Dystrophy. You can view a list of Dr. Gihan I. Tennekoon's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Gihan I. Tennekoon accept my insurance?

Dr. Gihan I. Tennekoon accepts most major insurance plans, including Humana. We recommend calling the office directly at 215-590-1000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tennekoon's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile